By Judy George
Source Medpagetoday
Low doses of lithium aspartate did not successfully treat neurologic symptoms of long COVID, a randomized, double-blind, placebo-controlled trial showed.
In a study of 52 people with long COVID, lithium aspartate at 10 to 15 mg/day yielded no significant improvement in fatigue and cognitive dysfunction scores at 3 weeks compared with placebo, reported Thomas Guttuso Jr., MD, of the University at Buffalo in New York, and co-authors in JAMA Network Openopens in a new tab or window.
The primary endpoint was the change in the sum of Fatigue Severity Scale-7 (FSS-7) and Brain Fog Severity Scale (BFSS) scores. Scores for each scale can range from 7 to 49, with higher scores indicating more severe symptoms.
Read more https://www.medpagetoday.com/neurology/longcovid/112226